Both GIP and GLP1 are susceptible to degradation by the enzyme dipeptidyl peptidase 4 (DPP-4), which has prompted the development of DPP-4 inhibitors as a treatment for type 2 diabetes mellitus. Here, GIP is linked to type 2 diabetes mellitus.